Ubs Group Ag 4 D Molecular Therapeutics, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 236,445 shares of FDMT stock, worth $945,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
236,445
Previous 97,564
142.35%
Holding current value
$945,780
Previous $543,000
40.52%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FDMT
# of Institutions
128Shares Held
43.5MCall Options Held
25.8KPut Options Held
33.4K-
Black Rock Inc. New York, NY4.9MShares$19.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$18.3 Million0.31% of portfolio
-
Bvf Inc San Francisco, CA4.56MShares$18.2 Million0.65% of portfolio
-
Goldman Sachs Group Inc New York, NY4.17MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$11 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $130M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...